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Abstract: The frequency of LA in 50 women with intact pregnancy, age range 26 to 39 years, 
but with past history of at least 2 lost pregnancies, was determined using coagulation-based 
assays. Most (68%) of the pregnant women were in the first trimester. Venous blood (4.5 mL) 
carefully collected from each of the subjects and also the controls (normal relative donors) was 
put in 0.5 mL of 3.8% citrate (ratio 9:1). The blood was quickly centrifuged at 1500 g; platelet-
poor plasma was separated and frozen at −30°C until analyzed. The control plasma was pooled 
and dispensed in 2 mL aliquots. Partial thromboplastin time with kaolin (PTTk) (against the 
control samples for comparison) and kaolin clotting time (KCT) were determined on each of the 
test samples using standard laboratory procedures. Prolonged PTTk was obtained in 36 patients 
(72%). KCT was obtained through mixtures of patients’ plasma with pooled control plasma 
(P:C) at 100:0; 0.8:0.2; 0.6:0.4; 0.5:0.5; 0.4:0.6; 0.2:0.8; 0:100; and lin-lin graph paper was 
used to plot out each of these dilutions against their respective clotting time in seconds. The 
interpreted graph showed that 12 (24%) had LA, while 3 (6%) had LA with cofactor. This high 
frequency necessitates regular screening for LA in pregnant women with a history of recurrent 
fetal loss at any gestational age.
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Introduction
The lupus anticoagulant (LA), most commonly an immunoglobulin, is an immediate-
acting coagulation inhibitor found in a variety of autoimmune disorders and sometimes 
found in otherwise healthy individuals.1 It appears to be directed specifically against the 
phospholipids moiety of prothrombinase complex formed by the interaction of   factors 
Xa, Va, platelet phospholipids, and calcium.2 It was first described in 1952.3 and its 
strong association with thromboembolic phenomenon, spontaneous miscarriage, and 
stillbirth was established.4–6
LA is an acquired autoantibody that binds to phospholipids’ active coagulation 
factors, which slows down the rate of thrombin generation and therefore retards clot 
formation in vitro,6 but promotes both venous and arterial thrombosis in vivo.7 This 
paradoxical association between in vitro anticoagulant effect and in vivo prothrombotic 
state activity of this autoantibody is not fully understood.
While antiphospholipid syndrome (APS) is known to be one of the most important 
causes of acquired hypercoagulable states8 and specifically causes late pregnancy 
loss, some studies found an association of 7% to 10% between recurrent spontaneous 
abortions in the first trimester and LA.6Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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Placental vessel thrombosis with ischemia,9 which 
starts early in pregnancy, and spiral artery vasculopathy,10 
which begins at about 8 weeks and is complete by 16 to 
20 weeks of gestation, are regarded as the causes of preg-
nancy loss.
Information about LA frequency in pregnant women 
with history of recurrent fetal loss is sparse in this part of 
the world, hence this study.
Materials and methods
subjects
Before the study began, approval was obtained from the 
ethical review committee of Oyo State Hospitals Man-
agement Board and informed consent from individual 
patients. Fifty women with intact pregnancy but who had 
had at least two previous unexplained pregnancy losses 
(ie, at least gravida 3), irrespective of their gestational 
age, were consecutively recruited into the study at the 
antenatal clinic of Adeoyo Maternity Hospital, Yemetu, 
Ibadan between January and April 1998. The age range 
was 26 to 39 years (average 31.6 years). Their antenatal 
records did not show comorbidities attributable to preg-
nancy loss.
sample collection
Venous blood (4.5 mL) was carefully collected through 
clean venupucture from each patient into a clean plastic 
tube containing 0.5 mL of 3.8% trisodium citrate (9 parts 
venous blood: 1 part anticoagulant). After thorough but gentle 
  mixing, the sample was centrifuged for 15 minutes at 1500 g 
at 25°C and platelet-poor plasma (PPP) was immediately and 
carefully aspirated and stored on ice in the freezer at −20°C 
prior to use.
Using a similar method PPP was obtained from each of 
the individual’s voluntary relative donors, which was pooled 
but discounted and stored in 2 mL aliquot at −20°C.
coagulation tests
Prothrombin time was determined by the original technique 
by Quick.11 Also partial thromboplastin time with kaolin 
was performed using the original method by Proctor and 
Rapparport.12
A kaolin clotting time (KCT) test, which is essentially an 
activated partial thromboplastin test but without any added 
phospholipid, was performed as previously described by 
Exner et al13,14 by preincubating 0.2 mL of citrated plasma 
with 0.1 mL of kaolin suspension (20 g/L in tris buffer pH 
7.4) for 3 minutes at 37°C.
Method
A mixing experiment was performed using dilutions of nor-
mal patient plasma prepared as shown in Table 1. Kaolin is 
added and then calcium to initiate coagulation. The KCT is 
the time from adding calcium to clot formation.
KCT ratio,14 ie, a ratio of KCT at 20% test plasma to 
KCT at 100% normal control plasma, was then calculated 
for each of the samples
KCT (80% normal: 20% test)
KCT 100% normal:
1.2 =≥
A ratio of $1.2 is considered positive for a lupus 
anticoagulant.
Results
Out of the 50 recruited pregnant women, 34 (68%), 7 
(14%), and 9 (18%) were in first, second, and third trimester, 
respectively.
Table 2 summarizes the outcome and interpretation of 
results in 50 pregnant women with history of fetal loss. The 
percentage dilution of neat/Test (N/T) plasma was plotted 
against time on a Lin-Lin graph for the 15 patients (30%) that 
had prolonged KCT; of these, 12 (24%) showed graphical 
evidence of LA in circulation and 3 (6%) showed graphical 
evidence of LA as well as deficiency in the cofactor necessary 
for full inhibitory effect.
Discussion
The APS is defined by the presence of antiphospholipid 
antibody or LA, usually in high titer, and any or all of the 
following clinical events: recurrent thromboses, recurrent 
fetal losses, and thrombocytopenia.15 Also Livedo reticularis 
Table 2 Outcome of partial thromboplastin time with kaolin 
(PTTk) and kaolin clotting time (KcT) in 50 pregnant women with 
recurrent pregnancy loss
Tests n Within  
normal
Mild  
prolongation
Very  
prolonged
PTTk 50 14 − 36 (72%)
KcT 50 35 3 (6%)  
(LA + cofactor)
12 (24%)  
(LA in circulation)
Abbreviation: LA, lupus anticoagulant.
Table 1 Dilutions of normal patient plasma
Normal plasma Patient plasma
100% 0%
90% 10%
80% 20%
50% 50%
20% 80%
10% 90%Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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is considered to be an additional marker for the disease.16 
Antiphospholipid antibody is identified either with an enzyme 
linked immunosorbent assay (ELISA), which commonly 
uses cardiolipin as the phospholipid’s antigen or by finding 
an LA with clotting tests. While ELISA for antiphospholipid 
antibody is known to be sensitive, but not very specific for 
predicting clinical events, LA with clotting tests, on the other 
hand, are specific but less sensitive.17 Although antiphospho-
lipid antibody thus occurs in a variety of situations in healthy 
individuals, in association with infections such as syphilis, 
in HIV-1, hepatitis C, and cytomegalovirus and in relation 
to medications, autoimmune antiphospholipid antibodies 
have higher titers and are more commonly of IgG isotype 
(mainly IgG2 and IgG4 subclasses), have higher avidity, and 
require presence of a cofactor.15,17,18 APS is a heterogeneous 
disorder both in terms of clinical manifestation and the range 
of autoantibodies.
Although antiphospholpid antibody causes prolonga-
tion of phospholipid-dependent clotting tests in vitro, it 
causes thrombosis in vivo. Different mechanisms thought 
to be responsible for this in vivo thrombosis and ischemia 
include inhibition by antibodies of antithromb-independent 
anticoagulant mechanisms, activated protein C, and inhibi-
tion of fibrinolysis.19 Other mechanisms are increased plasma 
concentration of soluble tissue factor and tissue pathway 
inhibitor, increased monocyte expression of tissue factor, and 
procoagulant activity in some patients with the syndrome.20 
Also, the autoantibody can inhibit prostacyclin secretion 
and promote release of von Willebrand factor by endothelia 
cells in vitro.21,22 Finally, platelet activation also plays a 
role in APS, particularly in arterial thrombosis. Therefore a 
thrombotic basis for pregnancy failure in APS is highly sup-
ported by the finding of decidual vasculopathy and placental 
infarction observed by Rand et al.23
In the present study, 60% of the patients have prolonged 
prothrombin time (18% mildly prolonged and 42% severely 
prolonged). This phenomenon has been observed in the past 
that LA occasionally increases the prothrombin time, and in 
turn the international normalized ratio, and therefore monitor-
ing anticoagulation with warfarin becomes difficult.24,25
Also our results agree with those of Haywood and Brown26 
who observed approximately 10% to 15% presence of LA in 
all the patients undergoing recurrent pregnancy loss.
The diagnosis of LA requires a high degree of suspicion. 
Many other manifestations should arouse this high degree of 
suspicion for LA apart from recurrent fetal loss, including 
unexplained thrombocytopenia, pulmonary hypertension, 
history of thrombotic events, cerebral vascular diseases in the 
young, unexplained infertility, autoimmune hemolytic anemia, 
thrombotic endocarditic mimicking rheumatic heart disease 
without history, and other features of rheumatic fever.
This high prevalence cannot be solely attributable to 
primary APS bearing in mind the heterogeneous nature of 
the antibody and the protean manifestation of its clinical 
picture. As enumerated by Greaves7 LA is also detectable 
in association with infections, ie, viral infections such as 
HIV-1, varicella, and hepatitis C, bacteria infections such 
as syphilis, and parasitic infections such malaria, which is 
endemic in this part of the world. Also various drugs such 
as guanidine, hydralazine, procainamide, and phenytoin may 
be responsible, as may be miscellaneous associations such as 
sickle cell disease, autoimmune hemolytic anemia, and auto-
immune thrombocytopenia. Therefore strong relevant clinical 
information is required to make a meaningful decision.
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